Could a Copper-Lowering drug help stop Triple-Negative breast cancer recurrence?

NCT ID NCT06134375

Recruiting now Disease control Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a drug called tetrathiomolybdate (TM) to standard chemotherapy (capecitabine) can reduce the risk of cancer spreading in people with high-risk triple-negative breast cancer. The trial has two parts: first, a small safety phase, then a larger randomized phase comparing the combination to capecitabine alone. About 204 participants who have completed initial treatment but still have signs of residual disease will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tetrathiomolybdate (TM) and capecitabine
What this could lead to: If successful, this could lead to a new treatment option that lowers the chance of breast cancer spreading in patients at high risk of relapse.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are not proven yet. Adding TM may cause side effects or not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESIDUAL DISEASE TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center
RECRUITING

Lebanon, New Hampshire, 03756, United States
Indiana University Simon Cancer Center
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
NYU Langone perimutter Cancer Center
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.